Quarterly ResultAug 13, 2026, 07:46 AM
Karyopharm Raises Going Concern Doubt; Q2 Net Loss $(67)M
AI Summary
Karyopharm Therapeutics Inc. has raised substantial doubt about its ability to continue as a going concern within the next year, citing insufficient capital resources beyond September 2026. The company faces a $15.8 million debt principal payment on September 10, 2026, which would trigger a default on its term loan. For the second quarter of 2026, Karyopharm reported a net loss of $(67.0) million on total revenue of $33.4 million, compared to a net loss of $(37.3) million on $37.9 million revenue in the prior year's quarter. The company is actively evaluating financing opportunities and strategic alternatives.
Key Highlights
- Karyopharm raised substantial doubt about its ability to continue as a going concern within one year.
- Existing liquidity is expected to fund operations only into September 2026.
- A $15.8 million principal payment due September 10, 2026, could trigger a term loan default.
- Q2 2026 net loss increased to $(67.0) million from $(37.3) million in Q2 2025.
- Q2 2026 total revenue decreased to $33.4 million from $37.9 million in Q2 2025.
- Cash and cash equivalents were $55.0 million as of June 30, 2026.
- Issued common stock and warrants for $30.0 million in a private placement offering.
- Stockholders approved an increase of 3.0 million shares for the 2022 Equity Incentive Plan.
Price Impact
More from KPTI